A phase 3 study published in the New England Journal of Medicine suggests there are benefits to both blood and marrow stem cell transplants, but no significant survival differences were found. Researchers from John Theurer Cancer Center played a key role in this groundbreaking study.
Researchers at John Theurer Cancer Center found carfilzomib to be clinically significant in responding heavily-pretreated patients with relapsed and refractory multiple myeloma. In the multi-center phase IIb study, ORR was 23.7% with median DOR of 7.8 months.
The John Theurer Cancer Center will present research on multiple myeloma and leukemia, including combination therapies and salvage therapy for acute myeloid leukemia. The center's focus on bolstering its research program is part of its continued effort to provide comprehensive cancer care.
The John Theurer Cancer Center is participating in a landmark clinical trial to develop personalized treatments for patients with multiple myeloma. The study aims to accelerate translational research into therapeutic breakthroughs, leveraging genomic portraits and tissue sampling.
Researchers shared findings on new treatments, predicting treatment outcomes, and patient quality of life issues. A phase II study of carfilzomib showed significant responses in patients with relapsed multiple myeloma.
Researchers at John Theurer Cancer Center found that patients with more partner support experience less distress after stem cell transplants. The study suggests that social support plays a crucial role in improving patient outcomes and quality of life.
Researchers sequenced the genome of multiple myeloma in a landmark study, identifying mutations in genes involved in protein translation, blood coagulation, and histone methylation. The findings provide new insights into the disease's development and offer potential directions for targeted therapies.
The John Theurer Cancer Center orthopedic oncologist shares novel approaches to limb sparing surgery, improving patient care for tumors in difficult locations. The educational videos showcase state-of-the-art procedures for radical limb sparing surgery and reconstruction, benefiting patients globally.
Thea Friedman, oncology basic research director at the John Theurer Cancer Center, has received a $2 million NIH grant to advance blood and marrow transplant research. Her team aims to develop personalized transplantation techniques using T cell receptor analysis to separate donor cells responsible for graft-versus-host disease from th...
The John Theurer Cancer Center has showcased research advancements in lymphoma, multiple myeloma, stem cell transplantation, and leukemia. A study found that early autologous peripheral blood stem cell transplantation improved overall survival for patients with newly diagnosed multiple myeloma.
The John Theurer Cancer Center will unveil 40 cutting-edge studies at the 52nd ASH Annual Meeting, featuring research on lymphoma, multiple myeloma, and blood disorders. Six investigators were first authors of 13 studies, solidifying their leadership role in cancer treatment.
The John Theurer Cancer Center will present research on unique surgical techniques to treat bone cancers that preserve as much bone and soft tissue as possible. These techniques include endoprostheses, cryosurgery, and radiofrequency ablation, with the goal of reducing complications and improving patient outcomes.
Ipilimumab shows significant survival benefits in stage IV melanoma patients, with a median survival of 10 months. The FDA grants priority review status to this cancer treatment, providing new hope for those with devastating disease.
Researchers from the John Theurer Cancer Center have made exciting progress in elucidating the mechanisms of bortezomib in mantle cell lymphoma. The study identified biomarkers that can help guide patient selection and speed up the development of targeted cancer drugs.
The John Theurer Cancer Center is presenting 16 research abstracts on various areas of oncology during the ASCO Annual Meeting. These studies include Phase I and II trials for multiple myeloma, lymphoma, and cutaneous T-cell lymphoma treatments.
Researchers from John Theurer Cancer Center present studies on first-line treatments for aggressive lymphoma, the efficacy of genetically engineered cancer therapy, and the value of a commonly used tool for staging lymphoma. Findings include a high complete remission rate with rituximab-FND combination therapy and better survival rates...
Ihor S. Sawczuk, M.D., Co-Chief of the Division of Urologic Oncology, presents research on laparoscopic adrenalectomy and robot-assisted radical prostatectomy for recurrent prostate cancer. The John Theurer Cancer Center showcases its expertise in urologic oncology through these innovative treatments.
SNS-032 demonstrated safety and clinical activity in treating advanced B-cell malignancies such as chronic lymphocytic leukemia (CLL) and multiple myeloma. The drug inhibited cyclin-dependent kinases and caused apoptosis in cancer cells, showing potential anti-tumor effects.
The study found a significantly higher incidence of MDS among seniors, with alarming rates of complications such as heart attacks, diabetes, and sepsis. The disease also proved to be costly to treat, with median Medicare bills exceeding $16,000